Idorsia raises Sfr505m through share sale and CB to fund R&D

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
ABBs-Block Trades

Idorsia raises Sfr505m through share sale and CB to fund R&D

Aidan Gregory
July 11, 2018 04:45 PM
Pharma,

Idorsia, the Swiss biopharmaceutical company, has raised Sfr505m ($503.82m) to finance advanced clinical trials after a simultaneous share and convertible bond sale overnight in Zurich.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

SwitzerlandCredit SuisseEquityABBs-Block TradesEuropeEMEAGoldman Sachs
AG
Aidan Gregory
Gift this article